Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
As my here know my inlaw has a brain tumor, is cotara avail on the market now
LOL, PPHM POWER WE WIN ;)
All this talk of bavi is cotara part of pphm?
For all to read Mr smarterwookie u may have heard
My brother inlaw had a seizure and was Unconscious, turns out he has a golf ball size tumer in his head, frontal lobe
Outer side i had an interest in cancer for some time now, hard to believe it hit so close, ,, anyone got any suggestions on
What kinds of medication i could get him on or best known procedures please let me know im were going to get him to
UCLA HOSPITAL asap he was sent
Home on dilantin 300 mg for now
Nice research work Wook,
Johnnyrocket ur doing fine like many ya
Just got to decide what news is worth
Sifting through, its was obvious to me
From your halt message my DD was needed, visiting NASDAQ site told me
Of course this was a halt and why it was
For sure NEWS ( of the good kind)
well its for sure like a shot to the heart ,,, family member has tumor in the brain front right ,, golf ball sized, he never even knew it,,need something to stop the growth
in lay man tern what the best way to explain concolidation to the wife
loof I added mine #s
OL LOOFMAN'S CLAIRVOYANCE UPDATE (as of 1:00 pm Sept14)
NOT TOO LATE TO GIT IN!!!
To enter, PLEASE RESPOND TO LOOFMAN ONLY FOR CONTEST UPDATE TO ADD YOUR PREDICTION!
Git out yer crystal ball, (I use a special family jug) and share your prediction here.
What will the share price close at on October 31, 2012? Who ever gets the closest without going over wins a spooktacular prize package to include a signed 8x10 glossy of Tessi May, and a package of Loofman's Famous Fresh Kill Squirrel Jerky.
Only one submission per alias and no entries after 10/13/12. All rules made up by Loofman the way he wants to.
Current Clairvoyance Stats:
High Prediction = $30.78
Low Prediction = $2.25
Average Prediction (72 respondents) = $10.86
NEW!!! - LOOFMAN'S ACCU-ESTOMATER - (This estomater takes the current average prediction of total respondents, multiplies that number by .67 to factor in high hopes and irrational exhuberance. It then multiplies the new factor by .90 to adjust fer any lickered up responses. Any finally .25 cents is added back to the final total to adjust for the lack of clarity that some of the respondents crystal balls may have). DISCLAIMER: This estomater has been proven to be 99.9% accurate in previous use.
LOOFMAN'S CURRENT ACCU-ESTOMATER OCT. 31 PRICE PRODICTION = $6.80 PER SHARE
----- DrRocker is currently closest to ACCU-ESTOMATER with $6.66
1. Loofman - $7.77
2. sunstar - $11.11
3. patientlywaiting - $8.88
4. Drumstick - $5.66
5. cjgaddy - $4.55
6. BioPharm - $21.00
7. aikifredicist - $12.1531
8. Threes - $7.33
9. Geocappy1 - $6.47
10. wwtmm - $14.27
11, Tag89 - $24.89
12. JJPK - $20.00
13. Ithrnck55 - $2.25
14. EYEBUYSTOCKS - $4.59
15. Roger1 - $6.00
16. Thurly - $3.18
17. DrRocker $6.66
18. honestabe13 - $3.75
19. Green-Grine - $5.15
20. Serene - $12.67
21. Purpledawgs - $5.55
22. Porkchop11 - $4.9099
23. Robert C. Jonson - $10.50
24. MMignot - $19.04
25. Notuncoolish - $17.23
26. trg-442006 - $8.71
27. Hayward - $8.88
28. Bungler - $6.0748
29. AtonePPHM - $14.40
30. Volgoat - $10.31
31. dia76ca - $30.78
32. Nazzduck - $12.72
33. djohn - $10.86
34. PGG76109 - $19.67
35. drontle2 - $5.40
36. Vancouverbaggie - $8.50
37. asmarterwookie - $25.2012
38. rhyino - $15.52
39. StoneRoad - $28.00
40. Mahoney1 - $22.27
41. Tech Writer - $17.77
42. Jimsgtx - $9.48
43. bigwup - $9.98
44. Spankyvol - $13.98
45. PPHMFan - $7.69
46. Tarvacin - $3.20
47. Jnothpilot - $19.35
48. horselover45 - $19.41
49. md1225 - $16.20
50. Braumeister $8.75
51. alvaroc2 - $10.00
52. Corporalagarn - $7.55
53. gandorph120 - $6.32
54. SmarTrader - $8.02
55. Rolodog - $13.24
56. HeavyDutyGeorge - $15.62
57. BKT - $7.765
58. Mgaddy - $13.00
59. Baviman $4.25
60. eastcoastguy - $4.95
61. Tandberg1 - $9.33
62. freethemice - $19.95
63. CloakedProtector - $7.51
64. NOTBOB17 - $7.17
65. nh - $7.37
66. ROKKONN - $9.69
67. pphmlover - $9.99
68. bassman2012 - $5.76
69. Biochica - $5.29
70. Freedom255 - $6.50
71. tutone71 - $6.15
72. EZlibra - $7.39
73. Dukesboy - $6.78
Omg brother inlaw I live with would not wake up this morn
Diagnosed with tumor on right side brain ''''
Wife want drug for inlaw
Ok ill lighten up things a bit wife finished watching my sisters keeper on LMN
cable, as the show ends i say wonder how things will turn out with cancer in future with the a new drug to live longer
She Replied ya never happen as i never tell her about what i do as im trading her
401k so i tell her and then say have you seen your account lately, OMG
SHE'S IN A GOOD MOOD TONIGHT
SHE CANT STOP TALKING ABOUT PPHM
For sure im dukes everywhere
In losangles ca. Live here most of life
I agree not calling. I had called once to boast of a good call i thought I had, and sure enough he tells me.. he wouldn't poke it with a stick, to speculative SELL SELL SELL ...
BIOF was a stock ... I sold it all because of his word,
bought PPHM,wouldn't you know it the stock takes off the
same day PPHM that was my .50 cent gold mine ,,,,
PPHM holding tight not gonna let CRAMER toast me again!
If this turns out to be a $5 billion
Jackpot! approx what would share price be?
Mahoney1 your reply message is sent via email
Mahoney1 got your message get back to you soon. , thanks
Shareholders meeting info from Dukesboy shareholder
I live near area, and may have connections to hotel.,
as it was mentioned the we might like to meet
the night before for a PPHM shareholders dinner
I if requested can help with these matters
Thank you Dukesboy
Reuters) - A mid-stage trial of Peregrine Pharmaceuticals Inc's experimental drug bavituximab showed that it doubled the length of time lung cancer patients survived, supporting the company's plans to conduct a pivotal-stage study.
The Phase 2 trial, involving 121 previously treated patients, found that those given a lower dose of bavituximab plus chemotherapy lived for a median of 11.1 months compared with 5.6 months for those treated with chemotherapy alone.
Patients given a higher dose of the Peregrine drug lived for a median of 13.1 months - resulting in a pooled survival time of 12.1 months for the treated group, Peregrine said.
Final results could change since less than half of the bavituximab-treated patients have died, compared with 70 percent of the control group, said Dr David Gerber, associate professor of internal medicine at the University of Texas and a principal trial investigator.
The company had reported in May top-line results from the trial showing that the drug improved tumor response rates as well as the amount of time patients lived without their cancer getting worse.
"The fact that the surrogate endpoints of response rates and progression-free survival have translated into a survival advantage is a really big deal," said Steven King, Peregrine's chief executive officer.
He said Peregrine is currently in discussions with potential partners to move bavituximab into a pivotal-stage trial, which it aims to launch in the second quarter of next year.
The drug, given by intravenous infusion, is a genetically engineered antibody designed to target a lipid molecule found on tumor blood vessels that acts to suppress the body's immune system.
The antibody binds to the targeted molecule to reactivate "the immune response locally at the site of the tumor," allowing the immune system to combat cancer cells, said Joseph Shan, head of clinical and regulatory affairs at Peregrine.
He said there were no safety risks associated with bavituximab in the study.
Peregrine announced in March that a trial of the drug as an initial therapy for lung cancer patients did not show a benefit in terms of progression-free survival.
"At this point we haven't seen overall survival data," Shan said. "That is where we would expect to see the biggest impact - longer-term protection from the tumor."
He said overall survival results from the front-line trial will likely be available toward the end of the year.
Shares of Peregrine have risen nearly sixfold since late May when the company announced initial results from the second line lung cancer trial.
(Reporting by Deena Beasley in Los Angeles; editing by Matthew Lewis)
Peregrine doubles lung cancer survival in small trial
http://www.reuters.com/article/2012/09/07/us-peregrine-lungcancer-idUSBRE8860Y620120907
findit paste copy link ???
just made $2.00 a share on 1000 shares im ready to buy!
updates soon >>>>
E15 COMING BY EOY 2O15
holding steady in this market>>>
wow biofuels up today!
stand up to cancer on tonight folks
L2 ANYONE
Results are promising, but require phase III confirmation
At today’s Plenary Session, David Gerber and colleagues report on the results of a randomized phase II, placebo-controlled trial evaluating two different doses of bavituximab (1 or 3 mg/kg weekly) in combination with standard docetaxel 75 mg/m2 every three weeks.
"Results are promising, but require phase III confirmation."
Dr. Langer is the director of thoracic oncology at the Abramson Cancer Center and professor of medicine at The University of Pennsylvania in Philadelphia. He will be one of the discussants at the Plenary Session today at 12:30 p.m. in Grand Ballroom I-III.
"the name alone is obvious" lets hope he's on our side :)
DUKESBOY ONE BOARD GOOD LUCK ALL
Prez Obama said it praise the man that cures cancer
http://www.barchart.com/quotes/stocks/PPHM
STRONG BUY 96%
WILL THERE BE LIVE WEBCAST GUYS ????
FRIDAY 1:40PM CENTRAL TIME ( BE READY )
Gerber is scheduled to present the study results at 1:40 p.m. Central Time Friday at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
Read more: http://www.minyanville.com/sectors/biotech-pharma/articles/peregrine-pharmaceuticals-bavituximab-steven-king-lung/9/6/2012/id/43778#ixzz25j7xIAVf
Gerber is scheduled to present the study results at 1:40 p.m. Central Time Friday at the Chicago Multidisciplinary Symposium in Thoracic Oncology
Read more: http://www.minyanville.com/sectors/biotech-pharma/articles/peregrine-pharmaceuticals-bavituximab-steven-king-lung/9/6/2012/id/43778#ixzz25j1OxFhN
good job cj , i was excited to get your info!
dukesboy
Maybe well have similar trading as CELG
any thoughts ? Sure gonna be crazy tomorrow i can feel the pressure building, ,,,,, Kaboom North